Related Experiment Videos
Defective thrombus formation in mice lacking coagulation factor XII.
Thomas Renné1, Miroslava Pozgajová, Sabine Grüner
1Institute of Clinical Biochemistry and Pathobiochemistry, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine, University of Würzburg, 97078 Würzburg, Germany. thomas@renne.net
The Journal of Experimental Medicine
|July 13, 2005
Summary
Coagulation factor XII (FXII) is essential for blood clot formation and stabilization. FXII-deficient mice show impaired thrombus formation but are protected from thromboembolism, revealing FXII as a novel therapeutic target.
Area of Science:
- Hematology
- Vascular Biology
- Thrombosis Research
Background:
- Blood coagulation traditionally initiated by Factor VIIa and tissue factor.
- Coagulation Factor XII (FXII)-mediated fibrin formation is considered minor in vivo.
Purpose of the Study:
- To investigate the role of FXII in in vivo thrombus formation using FXII-deficient mice.
- To challenge the established understanding of the FXII-mediated intrinsic coagulation pathway.
Main Methods:
- Utilized FXII-deficient mice for in vivo studies.
- Employed intravital fluorescence microscopy and blood flow measurements in arterial beds.
- Assessed thrombus formation and stabilization, and response to thromboembolic challenges.
Main Results:
- FXII-deficient mice exhibited severe defects in forming and stabilizing platelet-rich occlusive thrombi.
- These mice were protected against collagen- and epinephrine-induced thromboembolism without spontaneous bleeding issues.
- Restoration of FXII in FXII-null mice re-established injury-induced thrombus formation.
Conclusions:
- FXII is essential for in vivo thrombus formation, contrary to previous beliefs.
- The FXII-mediated intrinsic pathway plays a critical role in clotting.
- FXII represents a promising novel target for developing antithrombotic therapies.